SILK · Silk Road Medical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.24M | $48.48M | - | $44.44M | $45.30M | $40.13M | - | $37.37M | $33.17M | $28.02M |
| Cost of Revenue | $12.74M | $11.98M | - | $12.05M | $13.00M | $12.53M | - | $9.31M | $9.01M | $8.58M |
| Gross Profit | $38.51M | $36.50M | - | $32.38M | $32.29M | $27.61M | - | $28.07M | $24.16M | $19.44M |
| R&D | $11.88M | $10.66M | - | $10.05M | $10.78M | $10.43M | - | $8.47M | $10.65M | $8.12M |
| SG&A | $43.82M | $40.77M | - | $36.01M | $35.83M | $34.08M | - | $28.82M | $27.70M | $27.27M |
| Total Operating Expenses | $55.70M | $51.44M | - | $46.06M | $46.61M | $44.52M | - | $37.29M | $38.35M | $35.40M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($17.20M) | ($14.93M) | - | ($13.67M) | ($14.32M) | ($16.91M) | - | ($9.23M) | ($14.19M) | ($15.95M) |
| Interest Expense | $1.73M | $1.72M | - | $1.73M | $1.71M | $1.69M | - | $1.71M | $1.03M | $621.0K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($16.60M) | ($14.14M) | - | ($12.79M) | ($13.48M) | ($16.46M) | - | ($10.32M) | ($15.40M) | ($16.68M) |
| EPS - Basic | ($0.42) | ($0.36) | - | ($0.33) | ($0.35) | ($0.43) | - | ($0.29) | ($0.44) | - |
| EPS - Diluted | ($0.42) | ($0.36) | - | ($0.33) | ($0.35) | ($0.43) | - | ($0.29) | ($0.44) | - |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.64M | $22.63M | $20.21M | $29.19M | $28.40M | $50.43M | $55.36M | $51.31M | $87.64M | $93.60M |
| Accounts Receivable | $26.25M | $27.20M | $23.57M | $21.78M | $21.52M | $19.96M | $18.01M | $17.02M | $15.78M | $13.88M |
| Inventory | $29.68M | $30.49M | $29.88M | $22.07M | $19.07M | $17.18M | $19.29M | $20.29M | $17.62M | $17.73M |
| Accounts Payable | $3.69M | $2.97M | $5.68M | $5.09M | $5.34M | $5.27M | $2.52M | $4.31M | $3.67M | $2.93M |
| Current Assets | $241.02M | $235.69M | $240.84M | $240.98M | $233.50M | $230.25M | $254.90M | $146.99M | $146.92M | $127.77M |
| Total Assets | $269.81M | $252.31M | $265.31M | $260.86M | $263.36M | $259.59M | $269.69M | $162.54M | $162.72M | $143.00M |
| Current Liabilities | $31.57M | $21.34M | $30.28M | $24.02M | $24.10M | $20.87M | $24.49M | $23.93M | $21.24M | $29.50M |
| Long-term Debt | $76.15M | $75.89M | $75.63M | $75.36M | $75.10M | $74.85M | $74.60M | $74.34M | $74.03M | $38.90M |
| Total Liabilities | $115.12M | $105.03M | $114.16M | $107.72M | $107.86M | $101.97M | $105.81M | $105.35M | $102.69M | $75.29M |
| Stockholders' Equity | $154.68M | $147.28M | $151.15M | $153.14M | $155.50M | $157.61M | $163.88M | $57.20M | $60.03M | $67.71M |
| Retained Earnings | ($430.19M) | ($413.59M) | ($399.45M) | ($386.44M) | ($373.66M) | ($360.17M) | ($343.71M) | ($331.10M) | ($320.78M) | ($305.38M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($15.32M) | - | - | - | ($12.15M) | - | - | - | ($14.72M) |
| Investing Cash Flow | - | $17.74M | - | - | - | $6.11M | - | - | - | ($2.07M) |
| Financing Cash Flow | - | - | - | - | - | $1.11M | - | - | - | $168.0K |
| CapEx | - | $388.0K | - | - | - | $287.0K | - | - | - | $2.07M |
| Free Cash Flow | - | ($15.71M) | - | - | - | ($12.43M) | - | - | - | ($16.80M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 75.1% | 75.3% | - | 72.9% | 71.3% | 68.8% | - | 75.1% | 72.8% | 69.4% |
| Operating margin | -33.6% | -30.8% | - | -30.8% | -31.6% | -42.1% | - | -24.7% | -42.8% | -56.9% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -32.4% | -29.2% | - | -28.8% | -29.8% | -41.0% | - | -27.6% | -46.4% | -59.5% |
| Free cash flow margin | - | -32.4% | - | - | - | -31.0% | - | - | - | -59.9% |
| FCF / Net income | - | 1.11 | - | - | - | 0.76 | - | - | - | 1.01 |
| R&D / Revenue | 23.2% | 22.0% | - | 22.6% | 23.8% | 26.0% | - | 22.7% | 32.1% | 29.0% |
| SG&A / Revenue | 85.5% | 84.1% | - | 81.0% | 79.1% | 84.9% | - | 77.1% | 83.5% | 97.3% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.2% | -5.6% | - | -4.9% | -5.1% | -6.3% | - | -6.3% | -9.5% | -11.7% |
| Return on equity | -10.7% | -9.6% | - | -8.4% | -8.7% | -10.4% | - | -18.0% | -25.7% | -24.6% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.63 | 11.05 | 7.95 | 10.03 | 9.69 | 11.03 | 10.41 | 6.14 | 6.92 | 4.33 |
| Quick ratio | 6.69 | 9.62 | 6.97 | 9.11 | 8.90 | 10.21 | 9.62 | 5.29 | 6.09 | 3.73 |
| Cash ratio | 0.72 | 1.06 | 0.67 | 1.22 | 1.18 | 2.42 | 2.26 | 2.14 | 4.13 | 3.17 |
| Leverage | ||||||||||
| Debt / Equity | 0.49 | 0.52 | 0.50 | 0.49 | 0.48 | 0.47 | 0.46 | 1.30 | 1.23 | 0.57 |
| Debt / Assets | 0.28 | 0.30 | 0.29 | 0.29 | 0.29 | 0.29 | 0.28 | 0.46 | 0.45 | 0.27 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -10.0x | -8.7x | - | -7.9x | -8.4x | -10.0x | - | -5.4x | -13.8x | -25.7x |
| Equity multiplier | 1.74 | 1.71 | 1.76 | 1.70 | 1.69 | 1.65 | 1.65 | 2.84 | 2.71 | 2.11 |
| Liabilities / Assets | 0.43 | 0.42 | 0.43 | 0.41 | 0.41 | 0.39 | 0.39 | 0.65 | 0.63 | 0.53 |
| Efficiency | ||||||||||
| Asset turnover | 0.19 | 0.19 | - | 0.17 | 0.17 | 0.15 | - | 0.23 | 0.20 | 0.20 |
| Inventory turnover | 0.43 | 0.39 | - | 0.55 | 0.68 | 0.73 | - | 0.46 | 0.51 | 0.48 |
| Days sales outstanding | 187d | 205d | - | 179d | 173d | 182d | - | 166d | 174d | 181d |
| Days inventory outstanding | 851d | 929d | - | 668d | 535d | 501d | - | 796d | 713d | 754d |
| Days payable outstanding | 106d | 90d | - | 154d | 150d | 154d | - | 169d | 148d | 125d |
| Cash conversion cycle | 932d | 1043d | - | 693d | 559d | 529d | - | 793d | 739d | 811d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 13.1% | 20.8% | - | 18.9% | 36.6% | 43.2% | - | 51.3% | 25.4% | 27.1% |
| Revenue CAGR (3y) | 24.7% | 30.0% | - | 30.3% | 44.2% | 28.5% | - | 30.0% | 30.5% | 30.0% |
| Revenue CAGR (5y) | 28.0% | 30.6% | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 19.2% | 32.2% | - | 15.4% | 33.7% | 42.0% | - | 50.7% | 21.7% | 17.7% |
| Operating income growth (YoY) | -20.1% | 11.7% | - | -48.2% | -0.9% | -6.0% | - | 30.6% | -42.6% | -57.0% |
| Net income growth (YoY) | -23.1% | 14.1% | - | -23.9% | 12.4% | 1.3% | - | 25.7% | -46.1% | -56.0% |
| EPS growth (YoY) | -20.0% | 16.3% | - | -13.8% | 20.5% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -26.3% | - | - | - | 26.0% | - | - | - | -39.5% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -0.5% | -6.6% | -7.8% | 167.7% | 159.0% | 132.8% | 106.8% | -35.1% | -37.6% | -33.1% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Silk Road Medical Inc against the 5 most active filers in the same SIC group.